Myriad Reaches New 52-Week High (MYGN)

NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Monday as it is currently trading at $26.78, above its previous 52-week high of $26.76 with 5,629 shares traded as of 9:30 a.m. ET. Average volume has been 747,600 shares over the past 30 days.

Myriad has a market cap of $2.21 billion and is part of the services sector and diversified services industry.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.

TheStreet Ratings rates Myriad as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Myriad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments